Quanterix downgraded to Market Perform from Outperform at Leerink

Leerink analyst Puneet Souda downgraded Quanterix (QTRX) to Market Perform from Outperform with a price target of $8, down from $12. Quanterix is expected to close its acquisition of Akoya Biosciences (AKYA) with amended deal terms and no requirement for shareholder vote, the analyst tells investors in a research note. The firm finds it challenging to see how Quanterix can execute on integration of Akoya at a time when the company is addressing its own supply-chain realignment to address tariffs. Quanterix also faces pressures in its core academic markets, adds Leerink. It believes expectations full-year growth estimates for both companies have to be cut given market headwinds.